Downregulation of MiR-31 stimulates expression of LATS2 via the hippo pathway and promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma.

Downregulation of MiR-31 stimulates expression of LATS2 via the hippo pathway and promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma.
复制标题

DOI:
10.1186/s13046-017-0622-1
复制
发表时间:
2017-11-16
期刊:
Journal of experimental & clinical cancer research : CR
影响因子:
--
通讯作者:
Song H
Song H
中科院分区:
其他
文献类型:
--
作者:
Gao Y;Yi J;Zhang K;Bai F;Feng B;Wang R;Chu X;Chen L;Song H

文献摘要

参考文献

被引文献

相似文献

mirna的失调通过协调抑制大量靶基因与癌症的发展有关。新出现的证据表明,miR-31在致瘤性中起双重作用。然而,miR-31是否在食管鳞状细胞癌(ESCC)中起致癌基因作用以及潜在的靶分子尚不清楚。研究了MiR-31在ESCC中的作用,并在ESCC的进展中确定了靶分子与EMT的关联。Western blot和qRT-PCR检测蛋白和mRNA水平。我们通过体内和体外功能实验研究了miR-31在ESCC细胞系中调节LATS2表达的作用。荧光素酶报告基因检测证实了LATS2是miR-31的潜在靶标。免疫组化法检测正常组织和ESCC组织中LATS2和TAZ的表达。LATS2是Hippo肿瘤抑制信号通路的一个组成部分。据报道,在食管癌中,LATS2的杂合性经常缺失。我们分析了miR-31和LATS2的相互表达调控,并证明在ESCC中,通过下调miR-31在转录后水平上上调LATS2的表达。此外,miR-31显著抑制了与Hippo通路关键分子LATS2 3′-UTR结合的mRNA的荧光素酶活性。然后,LATS2因此促进TAZ的易位,用免疫组织化学检测。miR-31沉默可显著抑制细胞增殖,诱导细胞凋亡,降低体外迁移/侵袭能力。LATS2通过抑制miR-31抑制ESCC细胞增殖和侵袭,以及体内小鼠异种移植模型。同时,LATS2的核定位限制了TAZ的磷酸化。然后,与低风险患者相比,高复发风险患者的TAZ表达水平明显升高,并且高表达与较差的生存率相关。我们的研究表明,miR-31的过表达通过Hippo通路抑制LATS2的表达并激活上皮-间质转化,从而在ESCC中发挥致癌作用。LATS2和TAZ有可能成为预测ESCC复发风险和预后的新型分子标志物。本文的在线版本(10.1186/s13046-017-0622-1)包含补充内容,授权用户可使用。
Dysregulation of miRNAs is associated with cancer development by coordinately suppressing abundant target genes. Emerging evidence indicates that miR-31 plays a dual role in tumorigenicity. However, whether miR-31 plays as an oncogene in esophageal squamous cell carcinoma (ESCC) and the potential target molecules are still unclear. MiR-31 role in ESCC was investigated and an association of the target molecules with EMT was identified in the progression of ESCC. Western blot assays and qRT-PCR was performed to detect the protein and mRNA levels. We investigated the role of miR-31 in the regulation of LATS2 expression in ESCC cell lines via functional assays both in vivo and in vitro. The luciferase reporter assays was conducted to confirm LATS2 is a potential target of miR-31. Immunohistochemistry was used to measure LATS2 and TAZ expression in normal and ESCC tissue. LATS2 is a component of the Hippo tumor-suppressive signaling pathway. Frequent loss of heterozygosity of LATS2 has been reported in esophageal cancer. We analyzed the reciprocal expression regulation of miR-31 and LATS2 and demonstrated that LATS2 expression was elevated by down-regulation of miR-31 at the post-transcriptional level in ESCC. Moreover, miR-31 significantly suppressed the luciferase activity of mRNA combined with the LATS2 3′-UTR, a key molecule in the Hippo pathway. Then, LATS2 consequently promoted the translocation of TAZ, which was examined using immunohistochemistry. Silencing of miR-31 significantly inhibited the cell proliferation, induced apoptosis and decreased the ability of migration/invasion in vitro. LATS2 impedes ESCC cell proliferation and invasion by suppressing miR-31, as well as mice xenograft model in vivo. Meanwhile, the nuclear localization of LATS2 constrained the phosphorylation of TAZ. Then, the expression level of TAZ was notably heightened with a high risk of recurrence compared to that observed in the low-risk patients, as well as, the higher expression associated with a poor survival. Our study demonstrated that overexpression of miR-31 undertook an oncogenic role in ESCC by repressing expression of LATS2 via the Hippo Pathway and activating epithelial-mesenchymal transition. LATS2 and TAZ could be potential novel molecular markers for predicting the risk of recurrence and prognosis of ESCC. The online version of this article (10.1186/s13046-017-0622-1) contains supplementary material, which is available to authorized users.
DOI: 10.1016/j.yexcr.2004.04.031
发表时间: 2004-08-15
影响因子: 3.7
作者:
Ke, HN;Pei, J;Tao, WF
通讯作者: Tao, WF
DOI: 10.1186/1476-4598-11-5
发表时间: 2012-01-30
期刊: Molecular cancer
影响因子: 37.3
作者:
Augoff K;McCue B;Plow EF;Sossey-Alaoui K
通讯作者: Sossey-Alaoui K
DOI: 10.1016/j.semcdb.2012.07.002
发表时间: 2012-09
影响因子: 7.3
作者:
Avruch, Joseph;Zhou, Dawang;Fitamant, Julien;Bardeesy, Nabeel;Mou, Fan;Barrufet, Laura Regue
通讯作者: Barrufet, Laura Regue
DOI: 10.1093/carcin/bgs204
发表时间: 2012-09-01
期刊: CARCINOGENESIS
影响因子: 4.7
作者:
Alder, Hansjuerg;Taccioli, Cristian;Fong, Louise Y. Y.
通讯作者: Fong, Louise Y. Y.
DOI: 10.4161/cc.22670
发表时间: 2012-12-01
期刊: CELL CYCLE
影响因子: 4.3
作者:
Fang, Ling;Du, William W.;Yang, Burton B.
通讯作者: Yang, Burton B.